Call Us: 888-488-5750

Facebook Linkedin

There’s that word again: transparency

When Mike Ferguson, President & CEO of the Self-Insurance Institute of America (SIIA) polled the audience recently at the organization’s Spring Forum, the number one topic attendees wanted to learn more about was price transparency.

No surprise, that. After all, the goal of health insurance and prescription drug plans is to make treatment available to the greatest number of people at the lowest possible cost.

Pricing transparency is a good idea that is also still a work in progress

Transparency is a big deal for us at VativoRx as well. Just last month we wrote about the topic:

“Both the government and PBM-driven efforts to create greater transparency toward the goal of lowering healthcare costs are moving quickly. Those efforts have begun to pay off in recent years – costs are already going down for prescriptions — and we expect that progress to continue through the 2020s.”

For more on pricing transparency and the PBM industry’s point-of-view, read our article, Using transparency to drive prescription costs lower.

When Drug Negotiation Reaches Part B

For years, Medicare drug price negotiation was mostly discussed as a Part D story. That changed in January, when CMS selected 15 drugs for the third cycle of negotiation, including the first drugs payable under Medicare Part B. Negotiations take place in 2026, and any negotiated prices from this cycle take effect in 2028.

Read More »
March 27, 2026

TrumpRx: What It Is and What to Watch

TrumpRx.gov has quickly become part of the national conversation on prescription affordability. For provider organizations, the value in tracking TrumpRx isn’t political; it’s operational. Programs like this can influence patient expectations, pricing conversations at the point of care, and the way stakeholders interpret “drug cost” when list, net, and out-of-pocket prices don’t align.

Read More »
February 11, 2026